PCI Biotech Holding ASA
OSE:PCIB
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
PCI Biotech Holding ASA
OSE:PCIB
|
NO |
|
G
|
GuocoLand (Malaysia) Bhd
KLSE:GUOCO
|
MY |
|
U
|
Universal Biosensors Inc
ASX:UBI
|
AU |
|
I
|
Inflection Point Acquisition Corp II
NASDAQ:IPXX
|
US |
|
Decisive Dividend Corp
XTSX:DE
|
CA |
|
C
|
Companhia Energetica do Rio Grande do Norte Cosern
BOVESPA:CSRN6
|
BR |
|
J
|
Jinzai Food Group Co Ltd
SZSE:003000
|
CN |
|
FM Mattsson AB (publ)
STO:FMM B
|
SE |
|
R
|
Rimon Consulting & Management Services Ltd
TASE:RMON
|
IL |
|
N
|
Nouveau Global Ventures Ltd
BSE:531465
|
IN |
|
S
|
Suzhou YourBest New-type Materials Co Ltd
SZSE:301266
|
CN |
|
Mind Technology Inc
NASDAQ:MIND
|
US |
PCI Biotech Holding ASA
PCI Biotech Holding ASA engages in the research and development of biopharmaceutical products for cancer treatment. The company is headquartered in Oslo, Oslo. The company went IPO on 2008-06-18. Its activities are focused on the commercialization of a patented photochemical drug delivery technology for use in the localized cancer treatment. The Company’s products are based on the Photochemical Internalization (PCI) technology for light-directed drug delivery, used to enhance the effect of drugs by targeted illumination of the diseased areas of the body. The company focuses primarily on the drug candidate Amphinex, developed for treatment of head and neck cancer and bile duct cancer, as well as on the development of PCI for vaccination. As of December 31, 2011, it had a wholly owned subsidiary PCI Biotech AS and an affiliate PCIO Biotech Utibu, located in Iceland.
PCI Biotech Holding ASA engages in the research and development of biopharmaceutical products for cancer treatment. The company is headquartered in Oslo, Oslo. The company went IPO on 2008-06-18. Its activities are focused on the commercialization of a patented photochemical drug delivery technology for use in the localized cancer treatment. The Company’s products are based on the Photochemical Internalization (PCI) technology for light-directed drug delivery, used to enhance the effect of drugs by targeted illumination of the diseased areas of the body. The company focuses primarily on the drug candidate Amphinex, developed for treatment of head and neck cancer and bile duct cancer, as well as on the development of PCI for vaccination. As of December 31, 2011, it had a wholly owned subsidiary PCI Biotech AS and an affiliate PCIO Biotech Utibu, located in Iceland.
This earnings call has not been analyzed yet.
If you’d like us to analyze this earnings call, click the "Request Earnings Call Analysis" button below.
